Bone Biologics (BBLG) Equity Average (2011 - 2025)

Bone Biologics (BBLG) has 15 years of Equity Average data on file, last reported at $5.7 million in Q4 2025.

• Equity Average for Q4 2025 came in at $5.7 million, up 56.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.7 million (up 56.6% YoY), and the FY2025 annual result was $4.4 million, up 38.67% from the prior year.
• Equity Average fell to $5.7 million in Q4 2025 per BBLG's latest filing, from $6.3 million in the prior quarter.
• Over five years, Equity Average peaked at $6.3 million in Q1 2022 and troughed at -$14.9 million in Q3 2021.
• A 5-year average of $1.3 million and a median of $3.9 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average surged 221.04% in 2022, then tumbled 35.26% in 2023.
• A 5-year view of Equity Average shows it stood at -$4.3 million in 2021, then surged by 221.04% to $5.2 million in 2022, then plunged by 35.26% to $3.3 million in 2023, then increased by 8.61% to $3.6 million in 2024, then soared by 56.6% to $5.7 million in 2025.
• Business Quant data shows BBLG's Equity Average at $5.7 million in Q4 2025, $6.3 million in Q3 2025, and $4.8 million in Q2 2025.